Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
- DOI
- 10.1016/j.ebiom.2022.104375
- Published
- 2022-12
- Container
- eBioMedicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ebiom.2022.104375,
title = {Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial},
author = {DeAnna J. Friedman-Klabanoff and Megan Birkhold and Mara T. Short and Timothy R. Wilson and Claudio R. Meneses and Joshua R. Lacsina and Fabiano Oliveira and Shaden Kamhawi and Jesus G. Valenzuela and Sally Hunsberger and Allyson Mateja and Gregory Stoloff and Olga Pleguezuelos and Matthew J. Memoli and Matthew B. Laurens},
year = {2022},
journal = {eBioMedicine},
doi = {10.1016/j.ebiom.2022.104375},
url = {https://doi.org/10.1016/j.ebiom.2022.104375}
}RIS
TY - JOUR TI - Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial AU - DeAnna J. Friedman-Klabanoff AU - Megan Birkhold AU - Mara T. Short AU - Timothy R. Wilson AU - Claudio R. Meneses AU - Joshua R. Lacsina AU - Fabiano Oliveira AU - Shaden Kamhawi AU - Jesus G. Valenzuela AU - Sally Hunsberger AU - Allyson Mateja AU - Gregory Stoloff AU - Olga Pleguezuelos AU - Matthew J. Memoli AU - Matthew B. Laurens PY - 2022 JO - eBioMedicine DO - 10.1016/j.ebiom.2022.104375 UR - https://doi.org/10.1016/j.ebiom.2022.104375 ER -
APA
Friedman-Klabanoff, D. J., Birkhold, M., Short, M. T., Wilson, T. R., Meneses, C. R., Lacsina, J. R., Oliveira, F., Kamhawi, S., Valenzuela, J. G., Hunsberger, S., Mateja, A., Stoloff, G., Pleguezuelos, O., Memoli, M. J., & Laurens, M. B. (2022). Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial. eBioMedicine. https://doi.org/10.1016/j.ebiom.2022.104375
Source records
- crossref · retrieved 2026-09-26T18:46:08.604Z